trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-N-methylbenzamide | 1394012-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-N-methylbenzamide
• 英文别名: trans-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]-N-methylbenzamide
• CAS: 1394012-06-6
• 化学式: C₂₅H₃₅N₃O₃
• 分子量: 425.571
• InChiKey: UHCRWCSTKBZBFL-MGAMQBSKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  31.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.68
• 拓扑面积：
  79.46
• 氢给体数：
  3.0
• 氢受体数：
  3.0

反应信息

• 作为产物：
  描述：

  trans-4-Aminocyclohexanol 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 sodium hydride 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.0h， 生成 trans-4-[4-(3-adamantan-1-yl-ureido)cyclohexyloxy]-N-methylbenzamide
  参考文献：
  名称：

  Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

  摘要：

  To reduce the pro-angiogenic effects of sEH inhibition, a structure-activity relationship (SAR) study was performed by incorporating structural features of the anti-angiogenic multi-kinase inhibitor sorafenib into soluble epoxide hydrolase (sEH) inhibitors. The structural modifications of this series of molecules enabled the altering of selectivity towards the pro-angiogenic kinases C-RAF and vascular endothelial growth factor receptor-2 (VEGFR-2), while retaining their sEH inhibition. As a result, sEH inhibitors with greater potency against C-RAF and VEGFR-2 were obtained. Compound 4 (t-CUPM) possesses inhibition potency higher than sorafenib towards sEH but similar against C-RAF and VEGFR-2. Compound 7 (t-CUCB) selectively inhibits sEH, while inhibiting HUVEC cell proliferation, a potential anti-angiogenic property, without liver cancer cell cytotoxicity. The data presented suggest a potential rational approach to control the angiogenic responses stemming from sEH inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.011

文献信息

• [EN] SORAFENIB DERIVATIVES AS sEH INHIBITORS<br/>[FR] DÉRIVÉS DE SORAFÉNIB UTILISÉS EN TANT QU'INHIBITEURS DE LA SEH
  申请人：UNIV CALIFORNIA

  公开号：WO2012112570A1

  公开（公告）日：2012-08-23

  The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

  本发明提供了用于抑制可溶性环氧化物水解酶及相关疾病状况的化合物。
• SORAFENIB DERIVATIVES AS SEH INHIBITORS
  申请人：Hammock Bruce D.

  公开号：US20140088156A1

  公开（公告）日：2014-03-27

  The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

  本发明提供了用于抑制可溶性环氧酰胺酶及相关疾病状况的化合物。
• Treatment of inflammatory disorders in non-human mammals
  申请人：The Regents of the University of California

  公开号：US10383835B2

  公开（公告）日：2019-08-20

  The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.

  本发明涉及通过服用可溶性环氧化物水解酶抑制剂（作为唯一活性剂或与其他活性剂共同服用）来预防、减轻、抑制和逆转非人类哺乳动物的疼痛和炎症。
• Methods of improving cell-based therapy
  申请人：The Regents of the University of California

  公开号：US10369141B2

  公开（公告）日：2019-08-06

  Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

  本文提供了通过与增加环氧脂肪酸的产生和/或水平的制剂联合给药来改进基于细胞的疗法的方法，以及用于将干细胞与增加环氧脂肪酸的产生和/或水平的制剂联合给药的试剂盒、支架和贴片。
• Sorafenib derivatives as p21 inhibitors
  申请人：The Regents of the University of California

  公开号：US10449182B2

  公开（公告）日：2019-10-22

  The present invention provides sorafenib analogs for use in a method of treating a disease mediated by p21, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. The present invention also provides methods of inhibiting p21 in a cell comprising contacting the cell with an effective amount of a compound of formula I.

  本发明提供了用于治疗由p21介导的疾病的方法中的索拉非尼类似物，所述方法包括向有需要的受试者施用治疗有效量的式I化合物。本发明还提供了抑制细胞中p21的方法，包括使细胞与有效量的式I化合物接触。